Renovacor, Inc. (RCOR)

Overview

Renovacor is a biotechnology firm dedicated to developing targeted treatments aimed at improving the lives of individuals and families grappling with genetically-driven cardiovascular diseases and other related conditions. The company primarily focuses on dilated cardiomyopathy (DCM) that is linked to mutations in the BCL2-associated athanogene 3 (BAG3) gene. Established in 2013, Renovacor operates out of Greenwich, Connecticut, and strives to address the pressing medical needs of patients affected by these conditions through innovative therapeutic solutions.

Renovacor's flagship product candidate, REN-001, represents a cutting-edge approach to gene therapy. This treatment harnesses the capabilities of a recombinant adeno-associated virus 9 to deliver a healthy BAG3 gene directly into heart muscle cells (cardiomyocytes). The objective is to enhance BAG3 protein levels, potentially slowing down or halting the progression of BAG3-associated DCM. Additionally, Renovacor is committed to expanding its pipeline of BAG3-focused gene therapies, targeting multiple diseases that result from BAG3 gene mutations and affect protein expression and function.

Products and Services

• REN-001: This is Renovacor's lead candidate gene therapy, designed specifically to deliver a healthy BAG3 gene into heart muscle cells. By enhancing the production of BAG3 protein, REN-001 aims to mitigate the effects of dilated cardiomyopathy linked to BAG3 mutations, possibly improving the overall heart function and quality of life for patients.
• BAG3-focused Gene Therapies: Beyond REN-001, Renovacor is developing a portfolio of additional gene therapy candidates that are centered on the BAG3 gene. These therapies are aimed at addressing a variety of cardiovascular diseases and related conditions caused by mutations in the BAG3 gene, ultimately seeking to fulfill significant unmet medical needs in this area.